Year: 2025
Type: article
Abstract: In this issue of Blood, DeFilipp et al 1 report the results of a phase 2b clinical trial with RGI-2001, testing a promising new principle for preventing acute graft-versus-host disease (GVHD).The potential of allogeneic hematopoietic cell transplantation (allo-HCT) to cure hematological malignancies via graftversus-leukemia (GVL) effect is hampered by GVHD.Acute GVHD (aGVHD) is characterized by proliferation of alloreactive donor T cells leading to severe tissue damage of the target organs liver, gut, and skin.How to achieve optimal balance between GVL and GVHD for different donor types and graft sources is still a matter of debate.Although the backbone of calcineurin inhibitors and mycophenolate or methotrexate has long been used in the United States, it is mostly complemented by antithymocyte globulin (ATG)/anti-Tlymphocyte globulin formulations in Europe. 2 In 2023, posttransplantation cyclophosphamide (PTCy) was found to be superior to tacrolimus plus mycophenolate mofetil (ie, without ATG) 3 for transplantation of unmanipulated grafts of matched related and unrelated donors.Furthermore, ex vivo graft manipulation with selection/depletion of different cell populations has a long history in allo-HCT.However, it is currently not considered standard of care and only available in selected centers.
Source: Blood
Authors: Kristina Maas-Bauer, Claudia Wehr
Institution: University of Freiburg
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4415478398